Home » Stocks » CLGN

CollPlant Biotechnologies Ltd. (CLGN)

Stock Price: $13.75 USD -0.15 (-1.08%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 127.72M
Revenue (ttm) 6.14M
Net Income (ttm) -5.77M
Shares Out 9.91M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE 13.35
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $13.75
Previous Close $13.90
Change ($) -0.15
Change (%) -1.08%
Day's Open 13.91
Day's Range 13.55 - 13.83
Day's Volume 15,776
52-Week Range 6.00 - 24.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CollPlant (CLGN) is set to report earnings and revenues, and provide product updates when it releases first-quarter 2021 results.

3 days ago - Zacks Investment Research

Is (CLGN) Outperforming Other Medical Stocks This Year?

1 month ago - Zacks Investment Research

REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increas...

1 month ago - PRNewsWire

REHOVOT, Israel, March 26, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the full year ended December 31, 2020 and p...

1 month ago - PRNewsWire

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $12.26 in the latest trading session, marking a -1.84% move from the prior day.

1 month ago - Zacks Investment Research

Is (CLGN) Outperforming Other Medical Stocks This Year?

1 month ago - Zacks Investment Research

In the latest trading session, CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.33, marking a +1.76% move from the previous day.

1 month ago - Zacks Investment Research

Are you going to sit around to try and price a bottom or are you going to grab stocks that look obviously cheap today?

Other stocks mentioned: CRUS, HPR, IMMR, SPH, STFC
1 month ago - Zacks Investment Research

REHOVOT, Israel, March 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, will p...

2 months ago - PRNewsWire

REHOVOT, Israel, Feb. 25, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on February 24, 2021 it received a notice fro...

2 months ago - PRNewsWire

REHOVOT, Israel, Feb. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders. Dear share...

2 months ago - PRNewsWire

REHOVOT, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has closed the previously announced registered direct offering for the purchase and sa...

2 months ago - GlobeNewsWire

Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-...

Other stocks mentioned: CRVS, PRTA
2 months ago - Benzinga

REHOVOT, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has entered into definitive agreements with several healthcare-focused and other insti...

2 months ago - GlobeNewsWire

REHOVOT, Israel, Feb. 8, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced it has entered into a worldwide exclusive development and commercialization agreement for dermal an...

2 months ago - PRNewsWire

REHOVOT, Israel, Nov. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment of COVID-19...

5 months ago - PRNewsWire

REHOVOT, Israel, Sept. 16, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.

7 months ago - PRNewsWire

REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.

8 months ago - PRNewsWire

REHOVOT, Israel, Aug. 28, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the second quarter ended June 30, 2020 and ...

8 months ago - PRNewsWire

Is (CLGN) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Is (CLGN) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

11 months ago - Zacks Investment Research

REHOVOT, Israel, May 27, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, 2020 and p...

11 months ago - PRNewsWire

As of late, it has definitely been a great time to be an investor in CollPlant Biotechnologies.

1 year ago - Zacks Investment Research

These healthcare stocks have great financials now, and in the future. They all represent the future of medicine, and offer big growth.

Other stocks mentioned: DGX, DVA, NTRA, NVO, RMD, ZTS
1 year ago - InvestorPlace

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for October 11th

Other stocks mentioned: AMWD, CDE, CMPR
1 year ago - Zacks Investment Research

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tiss... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Yehiel Tal
Employees
52
Stock Exchange
NASDAQ
Ticker Symbol
CLGN
Full Company Profile

Financial Performance

In 2020, CLGN's revenue was $6.14 million, an increase of 164.75% compared to the previous year's $2.32 million. Losses were -$5.77 million, -48.28% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CLGN stock is "Buy" and the 12-month stock price forecast is 23.00.

Price Target
$23.00
Analyst Consensus: Buy